

Date: 01-08-2025

To,
Cooperate Relation Department
The BSE LIMITED
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter on 30th June, 2025.

Please find enclosed herewith Newspaper clippings of Un-Audited Financial Results for the quarter ended on **30th June, 2025** published in **FREE PRESS JOURNAL** and **NAVSHAKTI** on **1st Aug, 2025** in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on **31st July, 2025**.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,
For Colinz Laboratories Ltd.,

Dr. Mani L. S.
Director & Company Secretary
Din No : 00825886

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Mobile : 9137392123

* NAV-SHAKTI *

dt. 01/08/2025

नव शक्ति
marathi.freepressjournal.in

COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078.
(CIN NO : L24200MH1986PLC041128)

EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

S. No.	Particulars	QUARTER ENDED			YEAR ENDED
		Un-Audited		Audited	Audited
		30-Jun-25	30-Jun-24	31-Mar-25	31-Mar-25
1	Revenue from Operations	164.13	181.39	152.70	682.56
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	16.07	18.47	12.32	61.94
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	16.07	18.47	12.32	61.94
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	11.92	13.72	15.04	49.66
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	21.05	21.92	19.57	52.55
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annualised) (in Rs.)				
	1) Basic	0.47	0.54	0.60	1.97
	2) Diluted	0.47	0.54	0.60	1.97

NOTES :-

- 1) The above un-Audited financial statement for quarter ended June 30, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31st July, 2025 and Statutory Auditors of the Company have carried out limited review audit of the same.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.
- 3) Previous figures have been regrouped/ rearranged / reclassified, wherever necessary.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128

Dr. MANI L. S.
(Director & Chairman of the Meeting)
(DIN NO : 00825886)

MUMBAI.
31st July, 2025.



* FREE PRESS JOURNAL *

01-01/08/2025

Mumbai, Friday, August 1, 2025 | THE FREE PRESS JOURNAL | 23

COLINZ LABORATORIES LIMITED

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.
(CIN NO : L24200MH1986PLC041128)

EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2025

S. No.	Particulars	(Rs. In Lacs)			
		QUARTER ENDED		YEAR ENDED	
		Un-Audited		Audited	
		30-Jun-25	30-Jun-24	31-Mar-25	31-Mar-25
1	Revenue from Operations	164.13	181.39	152.70	682.56
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items).	16.07	18.47	12.32	61.94
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	16.07	18.47	12.32	61.94
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	11.92	13.72	15.04	49.66
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (Net of Tax).	21.05	21.92	19.57	52.55
6	Equity Share Capital (Face Value of Rs. 10/- each).	251.91	251.91	251.91	251.91
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.)				
	1) Basic	0.47	0.54	0.60	1.97
	2) Diluted	0.47	0.54	0.60	1.97

NOTES :-

- 1) The above un-Audited financial statement for quarter ended June 30, 2025 has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31st July, 2025 and Statutory Auditors of the Company have carried out limited review audit of the same.
- 2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.
- 3) Previous figures have been regrouped/ rearranged/ reclassified, wherever necessary.

For and on behalf of the Board
COLINZ LABORATORIES LTD.
CIN NO : L24200MH1986PLC041128
Dr. MANI L. S.
(Director & Chairman of the Meeting)
(DIN NO : 00825886)

MUMBAI.
31st July, 2025.

